Latest Whitepapers

This article explores how scientists are tackling the challenges and intensifying efforts to develop mRNA therapeutics for different diseases.

Genomics, proteomics and microbiomics are all useful tools in complex disease research. However, using these tools alone can risk critical knowledge gaps and leave researchers struggling to predict disease outcomes.

This whitepaper explores the latest reagents and software available to enhance tumor exome profiling for the generation of accurate, actionable clinical insights.

Proteomics provides crucial insights into cell signaling and disease mechanisms for biomedical and clinical research. Nevertheless, traditional LC-MS/MS methods have limitations in sensitivity, reproducibility and scalability within proteomics applications.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

Developing mRNA-based therapeutics is complex work, requiring highly skilled scientists, high-tech microfluidics platforms and sophisticated analytical equipment, and of course the mRNA itself.

This whitepaper highlights specific case studies that reveal how researchers are applying nanopore technology to a variety of sequencing techniques, including whole genome, targeted, RNA sequencing and single-cell analysis.

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Many regulatory guidelines state that cell banks and cultures used in the production of biologics must be tested for mycoplasma. Mycoplasma infections can cause severe problems in manufacturing as these organisms can alter DNA, RNA and modify host cell plasma membrane antigens.